Skip to main content

Advertisement

SpringerLink
Log in

HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer

  • Research Article
  • Published:
Tumor Biology

Abstract

The aim of this study is to evaluate the diagnostic performance of human epididymis protein 4 (HE4), cancer antigen 125 (Ca125) and the risk of ovarian malignancy algorithm (ROMA) in discriminating ovarian cancer from other benign gynaecological diseases. Serum levels of HE4 and Ca125 were measured in 119 women with benign gynaecological diseases, 29 patients with primary ovarian cancer, 32 patients with ovarian cancer on chemotherapy treatment (18 of them with progressive disease), 6 patients treated and free of disease and 32 healthy women. Sensitivity, specificity, positive and negative predictive values and positive and negative likelihood ratios (LR±) were calculated. Receiver operator characteristic (ROC) curves were constructed, and the areas under the curve (AUC) were calculated. High serum levels for HE4, Ca125 and ROMA were observed in cancer patients. HE4 was elevated in 12.6 %, Ca125 in 21 % and ROMA in 9.2 % in the benign group, but HE4 was not elevated in endometriosis. The AUC values for HE4, Ca125 and ROMA were 0.92, 0.911 and 0.945 respectively. The sensitivity for discriminating ovarian cancer from benign gynaecological diseases was 86.2 % for HE4 and Ca125 and 93.1 % for ROMA. The specificity was 87.4, 78.9 and 90.7 % for HE4, Ca125 and ROMA. The overall positive likelihood ratio (LR+) was 6.84 for HE4, 4.1 for Ca125 and 10.01 for ROMA. In premenopausal women, LR + was 11.86 for HE4, 5.11 for ROMA and 2.02 for Ca125. HE4 might be significant in the differential diagnosis of ovarian cancer. HE4 seems to be superior to Ca125 in terms of diagnostic performance of all premenopausal women. ROMA could help to discriminate in cases with any doubt with a high diagnostic accuracy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegel RXJ, Sala E. Cancer statistics. CA Cancer J Clin. 2010;60(5):277–300.

    Article  PubMed  Google Scholar 

  2. Paulsen T, Kjaerheim K, Kaern J, Tretli S, Trope C. Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals. Int J Gynecol Cancer. 2006;16 Suppl 1:11–7.

    Article  PubMed  Google Scholar 

  3. Engelen MJ, Kos HE, Willemse PH, Aalders JG, de Vries EG, Schaapveld M, et al. Surgery by consultant gynaecologic oncologists improves survival in patients with ovarian carcinoma. Cancer. 2006;106(3):589–98.

    Article  PubMed  Google Scholar 

  4. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54(12):e11–79.

    Article  CAS  PubMed  Google Scholar 

  5. Jacobs I, Bast Jr RC. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989;4(1):1–12.

    CAS  PubMed  Google Scholar 

  6. Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, et al. A prospective study of tumour markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumour Biol. 1992;13:278–86.

    Article  CAS  PubMed  Google Scholar 

  7. Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG 72.3 as tumour markers in patients with lung cancer: comparison with CYFRA 21–1, CEA, SCC and NSE. Tumour Biol. 2008;29:371–80.

    Article  CAS  PubMed  Google Scholar 

  8. Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumour markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol. 2009;30:121–9.

    Article  CAS  PubMed  Google Scholar 

  9. Markman M. The role of CA-125 in the management of ovarian cancer. Oncologist. 1997;2:6–9.

    CAS  PubMed  Google Scholar 

  10. Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991;37:1379–83.

    CAS  PubMed  Google Scholar 

  11. Menon U, Gentry-Maharaj A, Hallet R, Ryan A, Burnell M, Sharma A et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer , and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10 (4):327-340. available http://www.ncbi.nlm.nih.gov/pubmed/21642681

  12. Patridge E, Kreimer AR, Greenlee RT, et al. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol. 2009;113 (4):775-782. available http://www.ncbi.nlm.nih.gov/pubmed/19305319

  13. Bast Jr RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19–9, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984;149:553–9.

    Article  PubMed  Google Scholar 

  14. Bast Jr RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumour markers: CA 125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl 3:274–81.

    Article  PubMed  Google Scholar 

  15. van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, et al. Significance of serum CA 125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaecol Oncol. 2009;30:609–15.

    PubMed  Google Scholar 

  16. Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63(13):3695–700.

    PubMed  Google Scholar 

  17. Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162–9.

    Article  CAS  PubMed  Google Scholar 

  18. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumour biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402–8.

    Article  CAS  PubMed  Google Scholar 

  19. Havrilesky L, Whitehead C, Rubatt J, Cheek R, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374–82.

    Article  CAS  PubMed  Google Scholar 

  20. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast Jr RC, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117:440–5.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  21. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. The utility of serum human epididymis protein 4 (HE4) in patients with malignant and non malignant diseases: comparison with CA 125. Clin Chem. 2011;57(11):1534–44.

    Article  CAS  PubMed  Google Scholar 

  22. Galgano M, Hampton G, Frierson HJ. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847–53.

    CAS  PubMed  Google Scholar 

  23. Moore RG, Brown AK, Craig Miller M, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110:196–201.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  24. Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein (HE4) in benign and malignant diseases. Clin Chem Lab Med. 2012;50(12):2181–8.

    Article  CAS  PubMed  Google Scholar 

  25. Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Craig Miller M, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and Ca125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40–6.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Park Y, Lee JH, Hong DJ, Lee EY, Kim HS. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011;44(10–11):884–8. doi:10.1016/j.clinbiochem.2011.04.011.

    Article  CAS  PubMed  Google Scholar 

  27. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  28. Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:228–6.

    Article  PubMed Central  PubMed  Google Scholar 

  29. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267–77.

    Article  CAS  PubMed  Google Scholar 

  30. National Institute for Health and Clinical Excellence (NICE): Guidance. Ovarian cancer: the recognition and initial management of ovarian cancer. National Collaborative Centre for Cancer (UK). Cardiff, UK: National Collaborative Centre for Cancer, 2011.

  31. Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Drescher CW, et al. Use of Symptom Idex, Ca125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378–83.

    Article  PubMed Central  PubMed  Google Scholar 

  32. Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Fürst S, Mayr D, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA 125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011;49(12):2081–8.

    Article  CAS  PubMed  Google Scholar 

  33. Deeks JJ, Almant DG. Diagnostics test 4: likelihood ratios. BMJ. 2004;329(7458):168–9.

    Article  PubMed Central  PubMed  Google Scholar 

  34. Molina R, Escudero JM, Augé JM, Filella X, Foj L, Torne A, et al. HE4 a novel tumour marker for ovarian cancer: comparison with Ca125 and ROMA algoritm in patients with gynaecological diseases. Tumor Biol. 2011;32:1087–95.

    Article  CAS  Google Scholar 

  35. Park Y, Kim Y, Lee EY, Lee JH, Kim HS. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012;130:1136–44.

    Article  CAS  PubMed  Google Scholar 

  36. Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and Ca125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104:863–70.

    Article  PubMed Central  PubMed  Google Scholar 

  37. Bandiera E, Romani C, Specchia C, Zanotti L, Galli C, Ruggeri G, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnositic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–506.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  38. Yu S, Yang HJ, Xie SQ, Bao YX. Diagnostic value of HE4 for ovarian cancer: a meta-analysis. Clin Chem Lab Med. 2012;50(8):1439–46.

    Article  CAS  PubMed  Google Scholar 

  39. Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzolli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273–81.

    Article  CAS  PubMed  Google Scholar 

  40. Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynaecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):81–5.

    Article  PubMed  Google Scholar 

  41. Li F, Ruxiu T, Chang K, Wang F, Deng S, Lu W, et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and Ca125 in predicting epithelial ovarian cancer: A meta-analysis. BMC Cancer. 2012;12:258–76.

    Article  PubMed Central  PubMed  Google Scholar 

Download references

Conflict of interest

None

Author information

Authors and Affiliations

  1. Department of Clinical Laboratory, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea 31, 46009, Valencia, Spain

    Blanca Ortiz-Muñoz, Eduardo Aznar-Oroval, Pilar Perez Ballestero, Marina Sanchez Yepes & Tomás Garcia Lozano

  2. Department of Gynaecology, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea 31, 46009, Valencia, Spain

    Ana García García, Amparo Covisa Peris & Enrique García Garcia

  3. Department of Pathology, Fundación Instituto Valenciano de Oncología, C/Gregorio Gea 31, 46009, Valencia, Spain

    Carmen Illueca Ballester

Authors
  1. Blanca Ortiz-Muñoz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eduardo Aznar-Oroval
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana García García
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amparo Covisa Peris
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Pilar Perez Ballestero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marina Sanchez Yepes
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomás Garcia Lozano
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Carmen Illueca Ballester
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Enrique García Garcia
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Blanca Ortiz-Muñoz.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ortiz-Muñoz, B., Aznar-Oroval, E., García, A.G. et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumor Biol. 35, 7249–7258 (2014). https://doi.org/10.1007/s13277-014-1945-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-014-1945-6

Keywords

Search

Navigation